"We strive to support our customers in developing more and better biopharmaceuticals to treat patients. By continually innovating to create unique and unrivalled technologies, we bring practical solutions to the problems of the drug discovery and development process"
We provide solutions for customers working across cell line development:
VIEW OUR WEBINAR
"How a Top-5 Pharma Doubled the Speed of Cell Line Development"
Gene therapy was a hot topic in 2019, with many notable advances in the development of new medicines that could provide life-saving treatment for previously incurable diseases. There are many
Solentim, the world leader in instruments and workflow solutions for the Cell Line Development market, today reports another record year of sales in 2019. The Company recorded revenue growth from
Solentim, the leader in cell line development (CLD) instrumentation, is pleased to announce that Dr Duncan Borthwick will join the Company as the new Global Marketing Manager. Duncan has a
Company Information: About Solentim Solentim is a Life Sciences company committed to transforming the discovery and development of new biologics, to get materials into the clinic faster and to drive
Ian Taylor will share his expertise on purchasing the right platform solution at SLAS 2020 Solentim, a global leader in cell line development instrumentation, is pleased to announce it will
19th November 2019: Early last month saw publication of the latest perspectives from the FDA in a paper entitled: Considering “clonality”: A regulatory perspective on the importance of the clonal
What is clonality and why is it important Clonality is a crucial step in stable cell line development (CLD) for biotherapeutic workflows and one closely monitored by the medicines’ regulators.
Insights from the Oxford Global Cell Series UK Conference on the ongoing innovation driving new requirements for cell lines Author: Ian Taylor, Chief Commercial Officer, Solentim At last week’s Oxford
Eliminating enrichment steps in cell line development – reduce cell screening from 5000 to 200 clones per project
Coffee Morning Chat with Ferenc Boldog (ATUM) and Ian Taylor (Solentim): An expert discussion on the evolution of cell line development to negate the need for enrichment In the time
Bournemouth, UK, 8th October 2019: Solentim, the global leader in cell line development instrumentation, is delighted to announce that Mark Stockdale is starting at Solentim in a brand-new role as